Introduction {#tca12360-sec-0005}
============

Irinotecan, a camptothecin analog with anticancer activity through the inhibition of topoisomerase I, is widely used against solid tumors including lung, colorectal, gastric, gynecologic, and other types of cancer.[1](#tca12360-bib-0001){ref-type="ref"}, [2](#tca12360-bib-0002){ref-type="ref"}, [3](#tca12360-bib-0003){ref-type="ref"}, [4](#tca12360-bib-0004){ref-type="ref"} However, it causes adverse events, such as severe diarrhea and neutropenia in 13--25% of patients.[5](#tca12360-bib-0005){ref-type="ref"}, [6](#tca12360-bib-0006){ref-type="ref"} Irinotecan is a prodrug metabolized by carboxylesterase to form an active metabolite SN‐38, which is subsequently metabolized in the liver by uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (*UGT1A1*) to an inactive metabolite SN‐38 glucuronide (SN‐38G).[7](#tca12360-bib-0007){ref-type="ref"} Polymorphism of the *UGT1A1* gene is known to play an important role in irinotecan pharmacokinetics and severe toxicity.[8](#tca12360-bib-0008){ref-type="ref"} Decreased UGT1A1 activity resulting from genetic polymorphisms, such as *UGT1A1*\**28* and *UGT1A1*\**6*, are associated with increased SN‐38 and the occurrence of adverse events in irinotecan chemotherapy.[9](#tca12360-bib-0009){ref-type="ref"}, [10](#tca12360-bib-0010){ref-type="ref"}, [11](#tca12360-bib-0011){ref-type="ref"}, [12](#tca12360-bib-0012){ref-type="ref"}

The *UGT1A1*\**27* gene is in linkage disequilibrium with *UGT1A1*\**28*. Basic research has suggested that these polymorphisms exist together (haplotype), to reduce UGT enzyme activity.[13](#tca12360-bib-0013){ref-type="ref"}, [14](#tca12360-bib-0014){ref-type="ref"} However, the impact of *UGT1A1*\**27* on the toxicity of irinotecan is not well understood because its frequency is rare as 0.5--1%. Two previous clinical studies reported only seven patients with *UGT1A1*\**27* heterozygous gene polymorphisms who received irinotecan, with severe adverse events associated in six patients (86%).[11](#tca12360-bib-0011){ref-type="ref"}, [12](#tca12360-bib-0012){ref-type="ref"}, [13](#tca12360-bib-0013){ref-type="ref"}, [14](#tca12360-bib-0014){ref-type="ref"}, [15](#tca12360-bib-0015){ref-type="ref"}

Based on these results, we conducted a prospective study of the *UGT1A1*\**27* gene polymorphism. The main objective of the study was to determine the clinical impact of the *UGT1A1*\**27* gene polymorphism in patients who receive irinotecan‐based chemotherapy. A secondary objective was to evaluate the effects of gene polymorphisms *UGT1A1*\**28* and *UGT1A1*\**6* on irinotecan toxicity.

Methods {#tca12360-sec-0006}
=======

The study protocol was reviewed and approved by the protocol committee of the Lung Oncology Group in Kyusyu (LOGiK) and the ethics committee of each institution. Written informed consent was obtained from all study participants. This study was an independent collaborative (unsponsored) group study, and is registered at University Hospital Medical Information Network (UMIN) in Japan (UMIN000006164).

Patients and evaluation {#tca12360-sec-0007}
-----------------------

Eligibility criteria for patients in this study included: histologically and/or cytologically confirmed diagnosis of lung cancer; scheduled doses of irinotecan therapy of single ≥ 80 mg/m^2^, combination ≥ 50 mg/m^2^, radiation with single ≥ 50 mg/m^2^, or radiation with combination ≥ 40 mg/m^2^; age ≥ 20 years old; and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2. Exclusion criteria were: interstitial pneumonia determined by chest X‐ray; active infection; other active malignancies; pregnancy or possible pregnancy; mental disease which made it difficult to participate in the study; high fever ≥ 38 degree; severe complication of myocardial infarction within three months, uncontrolled angina pectoris, heart failure, diabetes mellitus and hypertension; diarrhea; and paralysis of the intestine or ileus.

Treatment {#tca12360-sec-0008}
---------

Treatment commenced within one week of enrollment. Irinotecan was administered as a single agent or in combination chemotherapy. Irinotecan dissolved in 250 mL of 5% dextrose was infused intravenously over 60 minutes. Irinotecan was postponed if the leukocyte count \< 3000/μL, platelet count \< 10 × 10^4^/μL, or any diarrhea occurred on the day or previous day, and was abandoned if the treatment was not administered within a week.

Genotyping assay and toxicity evaluation {#tca12360-sec-0009}
----------------------------------------

After blood sampling, genomic DNA were isolated from the 50 patients enrolled in the trial. *UGT1A1*\**28* and *UGT1A1*\**6* gene polymorphisms were analyzed using Invader technology (BML, Inc., Tokyo, Japan). In patients with confirmed *UGT1A1*\**28* heterozygous or homozygous gene polymorphisms, the existence of *UGT1A1*\**27* gene polymorphisms was investigated (Fig [1](#tca12360-fig-0001){ref-type="fig"}).

![Study scheme. Hetero, heterozygous; homo, homozygous; UGT1A1, uridine 5\'‐diphospho‐glucuronosyltransferase 1A1.](TCA-7-467-g001){#tca12360-fig-0001}

Drug toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v 3.0.[16](#tca12360-bib-0016){ref-type="ref"} Before the first cycle, blood cell count, urinalysis, and biochemistry tests were performed to assess renal and hepatic function and electrolytes. These tests were repeated during treatment, while other investigations were repeated, as necessary, to evaluate marker lesions.

Statistical analysis {#tca12360-sec-0010}
--------------------

The primary endpoint of this study was to determine the effect of the *UGT1A1*\**27* gene polymorphism on irinotecan therapy. Binominal distribution was used. The control consisted of all wild type *UGT1A1*\**28*, *UGT1A1*\**6*, and *UGT1A1*\**27*. Assuming a frequency control of 35%, *UGT1A1*\**27* gene polymorphism of 9%, grade 3--4 neutropenia of the control of 12.5%, and grade 3--4 neutropenia of the *UGT1A1*\**27* gene polymorphism of 50%, were established. These data are recorded in another of our studies, currently unpublished. Alpha = 0.05, beta = 0.08, and the estimated required number of *UGT1A1*\**27* gene polymorphism patients was 10. Considering a *UGT1A1*\**27* gene polymorphism frequency of 9%, the required sample size of this study was determined to be 111. Toxicities and efficacies were compared by the chi‐square test between patient groups divided according to *UGT1A1* gene polymorphisms. Progression‐free survival (PFS) was defined as the period from the start of irinotecan therapy to determination of treatment failure (death, documentation of disease progression) or the date of censoring at the last follow‐up examination. Overall survival (OS) was defined as the period from the start of irinotecan therapy until death from any cause or the date of censoring at the last follow‐up examination. Survival was evaluated by the Kaplan--Meier method, and differences in survival were analyzed by log‐rank test. The statistical significance level was set at *P* \< 0.05. All statistical analyses were performed using the SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).

Results {#tca12360-sec-0011}
=======

Fifty patients from two institutions were enrolled between October 2011 and December 2013. Two patients received lower starting doses of irinotecan, which was considered a protocol violation. Thus, the data of 48 patients were finally evaluated for the existence of *UGT1A1* gene polymorphisms, toxicity, response, and survival. The baseline patient characteristics are shown in Table [1](#tca12360-tbl-0001){ref-type="table-wrap"}. *UGT1A1* gene polymorphisms \*28/\*28, \*6/\*6, \*28/\*6, \*28/−, \*6/−, −/− observed 0, 1, 1, 7, 17 and 22, respectively (Table [2](#tca12360-tbl-0002){ref-type="table-wrap"}). The existence of *UGT1A1*\**27* was investigated in nine patients, including one ineligible patient with \*28/\*28; however, no *UGT1A1*\**27* gene polymorphisms were detected. The statistical commission recommended the study be concluded because it was unlikely that a target of 10 patients with *UGT1A1*\**27* polymorphisms could be achieved.

###### 

Patient characteristics

  Characteristics             Number of patients
  --------------------------- --------------------
  Gender                      
  Male                        41
  Female                      7
  Age (years)                 
  Median                      72
  Range                       51--87
  Performance status (ECOG)   
  0                           14
  1                           33
  2                           1
  Histology                   
  Adenocarcinoma              16
  Squamous cell carcinoma     15
  Small cell carcinoma        12
  Large cell carcinoma        1
  Others                      4

ECOG, Eastern Cooperative Oncology Group.

###### 

UGT1A1 gene polymorphism

        Total     \*28/\*28   \*6/\*6   \*28/\*6   \*28/−   \*6/−    −/−
  ----- --------- ----------- --------- ---------- -------- -------- --------
  *n*   48        0           1         1          7        17       22
  (%)   \(100\)   \(0\)       \(2\)     \(2\)      \(15\)   \(35\)   \(46\)

UGT1A1, uridine 5′‐diphospho‐glucuronosyltransferase 1A1.

Treatment administration {#tca12360-sec-0012}
------------------------

Irinotecan therapy was administered 153 times, at a median of three times per patient: once in seven patients (15%); twice in nine (19%); three in 19 (40%); four in three (6%); five in one (2%); and six in nine (19%). Irinotecan was used as combination chemotherapy in 32 (67%) patients, with cisplatin in 12 (25%); carboplatin in 10 (21%); gemcitabine in nine (19%); and paclitaxel in one (2%). In the remaining 16 patients (33%), only single irinotecan therapy was administered. Radiotherapies were administered concurrently in 23 (48%) patients, with a median of 60 Gy (range 40--61.4).

Toxicity {#tca12360-sec-0013}
--------

The grade 3--4 hematological and non‐hematological toxicities experienced by each patient and separated by *UGT1A1* gene polymorphism are listed in Table [3](#tca12360-tbl-0003){ref-type="table-wrap"}. Febrile neutropenia was observed at a higher tendency in patients with *UGT1A1*\**6* (32%) and *UGT1A1*\**28* (25%) gene polymorphisms, compared with wild type (14%), but had no significant difference. Grade 3--4 leukopenia and neutropenia were observed in six out of eight patients with *UGT1A1*\**28* gene polymorphisms, a significantly higher rate compared with wild type (75% vs. 32%, *P* = 0.049; 75% vs. 36%, *P* = 0.039, respectively). There was no difference between *UGT1A1* gene polymorphisms and wild type in regard to other toxicities. No pneumonitis or treatment‐related death occurred.

###### 

UGT1A1 gene polymorphism and toxicities (≥ grade 3)

  Side effect           \*6/\*6   \*28/\*6   \*28/−   \*6/−    −/−      *P*       
  --------------------- --------- ---------- -------- -------- -------- --------- -------
  Febrile neutropenia   0         0          2        6        3        0.589     0.230
  (%)                   \(0\)     \(0\)      \(29\)   \(35\)   \(14\)   ---       ---
  Leukopenia            0         0          6        9        7        0.049\*   0.486
  (%)                   \(0\)     \(0\)      \(86\)   \(53\)   \(32\)   ---       ---
  Neutropenia           1         0          6        9        8        0.039\*   0.465
  (%)                   \(100\)   \(0\)      \(86\)   \(53\)   \(36\)   ---       ---
  Anemia                0         0          0        4        2        1         0.390
  (%)                   \(0\)     \(0\)      \(0\)    \(24\)   \(9\)    ---       ---
  Thrombocytopenia      0         0          0        2        3        0.545     1
  (%)                   \(0\)     \(0\)      \(0\)    \(12\)   \(14\)   ---       ---
  Diarrhea              1         0          1        2        1        0.469     0.321
  (%)                   \(100\)   \(0\)      \(14\)   \(12\)   \(5\)    ---       ---
  Pneumonitis           0         0          0        0        0        1         1
  (%)                   \(0\)     \(0\)      \(0\)    \(0\)    \(0\)    ---       ---

\*Indicates significant difference. Statistic analyses were performed between "\*28/−, \*28/\*6" versus "−/−", and "\*6/\*6, \*28/\*6, \*6/−" versus "−/−." UGT1A1, uridine 5\'‐diphospho‐glucuronosyltransferase 1A1.

Efficacy {#tca12360-sec-0014}
--------

Of the 48 patients, 43 were assessable for tumor response. Objective tumor response was observed in 19 patients with an overall response rate of 44%. Tumor responses separated by *UGT1A1* gene polymorphisms are shown in Table [4](#tca12360-tbl-0004){ref-type="table-wrap"}. The tumor response of 57% in *UGT1A1*\**28* or *UGT1A1*\**6* gene polymorphisms was higher compared with 30% in wild type, but was not statistically different (*P* = 0.150). At survival assessment in June 2014, 27 patients were still alive, while 21 patients had died. The median PFS in the 48 patients was 6.8 months and the one‐year survival rate was 20.8%. Median PFS separated by UGT1A1 gene polymorphisms were 10.1 months in *UGT1A1*\**28* heterozygous, 8.5 in *UGT1A1*\**6* heterozygous, and 6.8 in both wild types, respectively. The median OS of 48 patients was 15.7 months and one and two‐year survival rates were 57.7% and 40.3%, respectively. Median OS separated by UGT1A1 gene polymorphisms was not reached in *UGT1A1*\**28* heterozygous, was 16.4 months in *UGT1A1*\**6* heterozygous, and 12.3 months in wild type, respectively. Kaplan--Meier plots and log‐rank tests showed no difference in PFS or OS between the three groups.

###### 

UGT1A1 gene polymorphism and tumor response (*n* = 43)

  *UGT1A1*   *n*   CR   PR   SD   PD   Response (%)   *P*
  ---------- ----- ---- ---- ---- ---- -------------- -------
  \*6/\*6    1     0    0    1    0    0              ---
  \*28/\*6   1     0    1    0    0    100            ---
  \*28/−     5     1    2    2    0    60             0.175
  \*6/−      16    0    9    7    0    56             0.312
  −/−        20    1    5    12   2    30             ---

*P*: compared with "−/−" by 2 × 2 Chi square & Fisher\'s test. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; UGT1A1, uridine 5\'‐diphospho‐glucuronosyltransferase 1A1.

Discussion {#tca12360-sec-0015}
==========

The objective of the present study, to determine the clinical impact of the *UGT1A1*\**27* gene polymorphism in patients receiving irinotecan‐based chemotherapy was not met, as we did not locate any patients with *UGT1A1*\**27* gene polymorphisms. We only searched for *UGT1A1*\**27* gene polymorphisms in patients with confirmed *UGT1A1*\**28* haplotype because the *UGT1A1*\**27* gene is in linkage disequilibrium with *UGT1A1*\**28* and they were thought to exist at all times together (haplotype); however, this hypothesis might be inaccurate.[13](#tca12360-bib-0013){ref-type="ref"}

Irinotecan is a semi‐synthetic water‐soluble prodrug metabolized by carboxylesterase to an active metabolite SN‐38, which has a 100--1000‐fold higher cytotoxicity than irinotecan. UGT further metabolizes SN‐38 to an inactive metabolite, SN‐38G.[17](#tca12360-bib-0017){ref-type="ref"} UGT1A1 is mainly expressed in the liver and is thought to be responsible for SN‐38 inactivation. *UGT1A1* genetic polymorphisms result in reduced enzyme activity and increased irinotecan toxicities. The most extensively studied gene polymorphism, *UGT1A1*\**28*, a variation of the TATA box, has been determined as a significant risk factor for severe irinotecan‐related toxicity in Caucasians and Asians.[10](#tca12360-bib-0010){ref-type="ref"}, [11](#tca12360-bib-0011){ref-type="ref"} In 2005, the United States Food and Drug Administration approved the diagnostic *UGT1A1* test, the Invader *UGT1A1* Molecular Assay (Third Wave Technologies Inc., Madison, WI, USA) and advised that patients with *UGT1A1*\**28* homozygous polymorphisms are at increased risk of irinotecan‐related neutropenia.[18](#tca12360-bib-0018){ref-type="ref"} *UGT1A1*\**6* single nucleotide polymorphisms (SNPs) in exon one of the *UGT1A1* gene (211G \> A \[G71R\]), which also represents an increased risk of irinotecan‐related toxicities, are mainly found in Asians.[11](#tca12360-bib-0011){ref-type="ref"}, [12](#tca12360-bib-0012){ref-type="ref"}, [19](#tca12360-bib-0019){ref-type="ref"} *UGT1A1*\**27*, the variant sequence in exon one (686C \> A \[Pro229Gln\]), reduces SN‐38 glucuronidation in vitro.[14](#tca12360-bib-0014){ref-type="ref"}, [20](#tca12360-bib-0020){ref-type="ref"} Sai *et al.* sequenced the *UGT1A1* gene in 195 Japanese subjects, including the enhancer/promoter regions, all exons, and their flanking regions, and assigned haplotypes using the detected SNPs.[13](#tca12360-bib-0013){ref-type="ref"} The *UGT1A1* haplotypes were classified into four groups (\**1*, \**60*, \**6*, \**28*); as \**28* and \**6* are present on a mutually exclusive chromosome, they exert an additive effect on irinotecan toxicity. By contrast, the \**27* allele had links to \**28* and was classified to the \**28* haplotype group. For this reason, the *UGT1A1*\**27* gene polymorphism was only investigated in patients who had *UGT1A1*\**28* gene polymorphisms.

To determine whether the \**27* haplotype exists with the \**28*, Ando *et al.* retrospectively investigated the impact of the *UGT1A1* genetic polymorphism in irinotecan‐related severe toxicity in 118 patients. In 18 patients (15.3%) heterozygous for the *UGT1A1*\**28* haplotype, one patient (0.8%) was heterozygous for *UGT1A1*\**27*. In seven patients (5.9%) homozygous for the *UGT1A1*\**28* haplotype, two patients (1.7%) were heterozygous for *UGT1A1*\**27*. Although three patients out of 118 (2.5%), is low, all three patients heterozygous for *UGT1A1*\**27* haplotypes existing with *UGT1A1*\**28* experienced severe toxicity after irinotecan chemotherapy. Thus, *UGT1A1*\**27* might considerably affect irinotecan susceptibility when it coexists with a variant sequence in the promoter *UGT1A1*\**28*. Minami *et al.* also found four additional \*27 haplotypes, including three heterozygous \*28 and one homozygous \*28, in addition to \*27 in their patients.[21](#tca12360-bib-0021){ref-type="ref"} Why, then, was the *UGT1A1*\**27* haplotype not found in our study? The first possible reason, although our method was correct, is that the *UGT1A1*\**27* haplotype is too rare; thus, *UGT1A1*\**27* does not have significant meaning for clinical practice. Second, *UGT1A1*\**27* may have medical significance but we did not find the haplotype in this population because we only searched for *UGT1A1*\**27* in patients with the *UGT1A1*\**28* polymorphisms. We did not investigate *UGT1A1*\**27* status in patients with wild type *UGT1A1*\**28*.

*UGT1A1*\**28* and *UGT1A1*\**6* polymorphisms were detected approximately half as often as both wild types (46%), followed by \**6* heterozygous (35%), and \**28* heterozygous (15%). Homozygous and both heterozygotes were rare (4%). The *UGT1A1*\**6* gene polymorphism is associated with severe irinotecan toxicity in Asians, which was confirmed by our study; however, our results did not reach statistical significance.[12](#tca12360-bib-0012){ref-type="ref"}, [22](#tca12360-bib-0022){ref-type="ref"} In patients with the *UGT1A1*\**28* gene polymorphism, including both heterozygous and homozygous types, grade 3--4 leukopenia and neutropenia were observed at a significantly higher frequency compared with wild type. Our results were consistent with previous studies in that *UGT1A1*\**28* gene polymorphisms are a significant risk factor for irinotecan‐related toxicities.[10](#tca12360-bib-0010){ref-type="ref"}, [11](#tca12360-bib-0011){ref-type="ref"} The United States Food and Drug Administration declared that patients with homozygous *UGT1A1*\**28* polymorphisms have an increased risk of neutropenia with irinotecan treatment.

In conclusion, our prospective study did not find the *UGT1A1*\**27* gene polymorphism, which may suggest that the *UGT1A1*\**27* gene polymorphism does not significantly predict severe irinotecan toxicity in cancer patients. By contrast, the *UGT1A1*\**28* gene polymorphism is associated with irinotecan‐related leukopenia and neutropenia.
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